Compare LSAK & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSAK | CYPH |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 321.1M |
| IPO Year | 2005 | 2019 |
| Metric | LSAK | CYPH |
|---|---|---|
| Price | $2.96 | $1.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 177.9K | ★ 13.1M |
| Earning Date | 11-04-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 102.63 | ★ 103.87 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $721,554,000.00 | $1,500,000.00 |
| Revenue This Year | $11.56 | N/A |
| Revenue Next Year | $14.39 | $590.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.38 | N/A |
| 52 Week Low | $3.15 | $0.49 |
| 52 Week High | $5.54 | $4.19 |
| Indicator | LSAK | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 26.57 | 37.62 |
| Support Level | N/A | $0.65 |
| Resistance Level | $4.95 | $3.42 |
| Average True Range (ATR) | 0.23 | 0.35 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 0.39 | 5.04 |
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates three reportable segments: Merchant, Consumer, and Enterprise. Merchant, which focuses on both formal and informal sector merchants. Consumer, which focuses on individuals who have historically been excluded from traditional financial services and to whom it offers transactional accounts (banking), insurance, lending (short-term loans), payments solutions and various value-added services; and Enterprise, which comprises large-scale corporate and government organizations, including but not limited to banks, mobile network operators (MNOs) and municipalities, and, through Recharger, landlords utilizing Recharger's prepaid electricity metering solution.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.